Currently, Farnesoid X receptor (FXR) agonists are promising for PSC and PBC, whereas PPAR agonists, anti-CCL24 antibodies based on eosinophil control, and apical sodium-dependent bile acid transporter (ASBT) inhibitors that regulate bile acid transporters are under development [153]. The gene discussed is SLC10A2; the disease is primary biliary cholangitis.